Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much as 22%.

The Danish drugmaker announced new data for its new weight-loss drug Amycretin Friday.

The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

In the latest trading session, Novo Nordisk (NVO) closed at $80.57, marking a -0.57% move from the previous day.

Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price negotiations in 2025.

Novo Nordisk (NYSE:NVO) shares plummeted after the US Medicare program announced it plans to include the firm's weight loss medications in its second round of price negotiations. Shares of the Dani...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday.

Novo Nordisk presents a compelling 'Strong Buy' opportunity with a 51% upside potential. NVO's financial strength is evident through its 74% historical average ROIC, 85% gross margin, and substanti...

Obesity is rising and in the last 35 years, has more than doubled. The world population in 1999 to today is 42% or 22 million adults with a body mass index of 40 or higher.

In the most recent trading session, Novo Nordisk (NVO) closed at $84.62, indicating a -1.9% shift from the previous trading day.

Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental obesity pill, and supply capacity for Ozempic and Wegovy.

In the closing of the recent trading day, Novo Nordisk (NVO) stood at $83.34, denoting a -1.99% change from the preceding trading day.

Novo Nordisk (NVO 0.15%) has sparked investor interest primarily because of its weight loss treatments.

VANCOUVER, British Columbia, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Novo Resources Corp. (TSX: NVO) (ASX: NVO) (OTCQB: NSRPF) announces that it has transitioned its trading platform from the OTCQX to th...

While Novo Nordisk's (NYSE: NVO) Ozempic has gotten most of the name recognition associated with weight-loss drugs, it's not the only drug in this category doing well. While Elon Musk recently show...